Supreme Court tosses Bristol Myers’ bid to revive $1.2B CAR-T case against Gilead

In the latest setback for Bristol Myers Squibb in a years-long legal tussle with Gilead over a CAR-T patent, the Supreme Court of the United States has declined to hear its petition to revive a $1.2 billion verdict.

At its core, Bristol Myers claimed that Gilead’s pioneering CAR-T, Yescarta, infringed...

Click to view original post